Neuroplasticity in Multiple Sclerosis: A Therapeutic Approach

Vitor do Amaral Poletti [a]

[a] Faculty of Biomedicine, Ritter dos Reis University Center, Porto Alegre, Brazil,, vitorpoletti@gmail.com

Abstract. Multiple Sclerosis is a complex and debilitating disease that affects the central nervous system, causing symptoms such as fatigue, muscle weakness, vision problems, and cognitive issues. New research suggests that neuroplasticity may be a promising therapeutic avenue for treating Multiple Sclerosis. This research involved an exclusive search on PubMed for articles related to this topic, using the keywords "neuroplasticity" and "multiple sclerosis." In total, 19 articles were found that explored this possibility, primarily in clinical studies conducted between 2013 and 2023. The analysis of these articles was carried out to identify trends, relevant outcomes, and research gaps. The results obtained demonstrate the efficacy of neuroplasticity-based treatments, highlighting the importance of personalized and multidisciplinary approaches in the treatment of Multiple Sclerosis based on neuroplasticity.

Keywords. Multiple Sclerosis, Neuroplasticity, Treatment, Rehabilitation, Clinical Trials, Disease Management.

1. Introduction

Neuroplasticity is a fascinating and fundamental phenomenon that challenges previously established concepts about the rigidity of the human brain, as described by Franz Gall and later refined by Paul Broca, who in 1861 concluded where the center of language was located based on a patient with a lesion in the posterior region of the frontal lobe [1]. Neuroplasticity, or cerebral plasticity, refers to the remarkable ability of the nervous system to adapt and reorganize its structures and functions in response to stimuli, experiences, and environmental changes.

This dynamic process occurs at various scales, from the reconfiguration of synaptic connections between neurons to the reorganization of entire brain regions [2]. Neuroplasticity plays an essential role in brain development during childhood, lifelong learning, recovery from neurological injuries, and adaptation to cognitive challenges [3,4]. It is a field of research that has revolutionized our understanding of the brain and offered promising perspectives for the treatment of neurological disorders and brain injuries, especially regarding neurodegenerative diseases.

Neurodegenerative diseases represent a complex and growing group of disorders that affect the nervous system, leading to progressive deterioration of nerve cells and, consequently, a variety of cognitive, motor, and behavioral dysfunctions [5]. These debilitating conditions include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, among others. Characterized by a gradual loss of neurons and protein alterations, these diseases have devastating consequences for affected individuals and their families.

As life expectancy increases worldwide, the impact of neurodegenerative diseases becomes more prominent and challenging [6]. Furthermore, these conditions represent a significant burden on healthcare systems and society as a whole [6]. Scientific efforts are increasingly focused on understanding the underlying causes, pathological mechanisms, and the development of therapeutic interventions to slow down or halt the progression of these diseases [4].

Multiple sclerosis (MS) is a chronic autoimmune neurological disease that affects the central nervous system, comprising the brain and spinal cord. This complex condition is characterized by an abnormal immune response that results in inflammation, demyelination, and damage to axons [7]. MS is one of the most prevalent neurological diseases worldwide, primarily affecting young and middle-aged adults, although it can manifest at any age [5].

The symptoms of MS can vary widely from person to person, encompassing chronic fatigue, muscle weakness, coordination problems, visual disturbances, sensory issues, and cognitive difficulties

[7]. Due to the diversity of clinical manifestations, multiple sclerosis is often challenging to diagnose and manage. While there is no definitive cure for MS, significant advances have been made in understanding the disease and developing therapies that can slow the condition's progression and alleviate symptoms [8].

In this article, we will examine the key characteristics of multiple sclerosis, exploring the latest scientific findings and therapeutic strategies aimed at harnessing neuroplasticity to improve the quality of life and treatment of these complex and debilitating conditions.

2. Methodology

For the completion of this review article, a search was conducted exclusively on PubMed using the keywords "neuroplasticity" and "multiple sclerosis," with a focus on clinical trials literature published between 2013 and 2023. Inclusion and exclusion criteria were rigorously applied to the titles and abstracts of the articles found. As inclusion criteria, we sought only those whose objectives addressed possibilities for the treatment of multiple sclerosis and its symptoms through the principles of neuroplasticity. We excluded those that did not have results or did not align with the inclusion criteria. The selected articles underwent in-depth reading and analysis, and their relevant information was extracted and categorized. Data synthesis and analysis resulted in the identification of trends, relevant findings, and research gaps. Finally, the findings were discussed, highlighting implications for multiple sclerosis treatment based on neuroplasticity, and a comprehensive list of bibliographic references was compiled to support the research.

3. Results

The search results revealed the identification of 21 articles that were carefully selected and subjected to a meticulous analysis as part of the study. Initially, none of the articles were excluded from the results. However, during the screening process, it was identified that two articles did not completely align with the established exclusion criteria, as they were only study protocols. Therefore, we were left with a total of 19 articles. The distribution of these articles according to the publication year can be seen in Figure 1. After a thorough analysis of those selected for this research, the results reveal a promising landscape regarding the use of neuroplasticity as a therapeutic approach for MS. Despite the various methodological approaches adopted in these studies, all converged toward the same central objective: investigating and applying the principles of neuroplasticity in the context of MS treatment.

These findings point to a remarkable consistency regarding the potential benefits that the usability of neuroplasticity can offer to patients with multiple sclerosis. Regardless of the specific approaches taken in each study, the results suggest that neuroplasticity has the potential to become a crucial pillar in managing this condition. These findings bolster confidence in the practical application of neuroplasticity as a viable therapeutic component. This represents a notable achievement in the field of MS research, providing a solid foundation for future investigations and treatments aimed at harnessing the full potential of neuroplasticity in the clinical setting.



Fig 1: Number of Clinical Trial articles published on PubMed between 2013 and 2023.

Furthermore, it is worth noting that the analyzed studies presented a wide diversity of methodologies to promote neuroplasticity in patients with multiple sclerosis. Among them, physical activity, ranging from resistance exercises to specialized rehabilitation techniques, proved effective in improving mobility and promoting neuroplastic adjustments [9-17]. Similarly, challenging cognitive activities, ranging from memory games to logical reasoning training programs, demonstrated potential for strengthening cognitive function [10,18-21].

Additionally, neuroelectric stimulation, in this case, by the method of transcranial direct current stimulation (tDCS) [17,22-25], a technique that employs controlled electrical currents to modulate neural activity (Figure 2). When used in conjunction with physical, cognitive, or both forms of stimulation, it may yield more effective results in reorganizing activities.



Fig. 2: Transcranial direct-current stimulation. tDCS setup (a) with red anode and black cathode sponge

electrodes placed on scalp and connected to tDCS device to pass 2 mA current through cortical tissue. A computational model (b) of electric field distribution for bifrontal electrode arrangement with the anode (red) over F3 and cathode (blue) over F4 [26]

There is also the possibility of using physiological resources to facilitate plasticity, such as Interleukin-1β, which may be a promising therapeutic target for enhancing synaptic plasticity and cognitive function in patients with MS [27]. Additionally, results indicate that treatment with OnabotulinumtoxinA (BoNT-A) significantly reduces the severity of tremors in MS patients and results in significant changes in brain activation in central sensorimotor integration areas, suggesting a reduction in negative neural plasticity associated with tremors [28].

This diversity of approaches (Figure 3) underscores the wealth of possibilities for promoting brain plasticity in patients with MS, paving the way for personalized and adaptable treatment strategies that can be tailored to the individual needs and preferences of each patient.



Fig 3: Quantity of different applied methodologies.

In summary, synthesizing the results, there is a considerable discrepancy between positive and negative findings regarding neuroplastic changes and the promising improvement of MS symptoms studied in the articles. Positive results account for a total of 84.21% of the articles studied in this review (Figure 4).



Fig. 4: Quantification of the results published by the articles. Green represents the positive results, while blue represents the negative.

4. Discussion

We can confidently assert that the use of neuroplasticity principles emerges as a promising therapeutic approach for the treatment of multiple sclerosis when used appropriately. While we acknowledge the complexity of this condition and the need to consider individual variations, it is encouraging to observe that neuroplasticity, when applied appropriately, shows the potential to enhance the quality of life for patients. This therapeutic approach offers a new realistic perspective for those facing multiple sclerosis, with the possibility of tangible improvements in mobility and cognition, though further studies and personalized adaptations are required to optimize outcomes for each patient.

This research demonstrates that neuroplasticity, when used in the right way, can be a promising treatment option for multiple sclerosis patients. It may pave the way for a more functional and fulfilling life for those living with this challenging condition.

While there is still much to be discovered, there is also the possibility of using induced pluripotent stem cells (iPSCs) to treat multiple sclerosis. There is growing evidence that these cells may be capable of promoting neuroplasticity and central nervous system repair (29). This could be a promising avenue for applying neuroplastic rehabilitation techniques; however, much research is still needed to better understand how these cells can be used for MS treatment and their effects on neural plasticity.

There is still much to understand about neuroplasticity. However, the applicability of the brain's plastic properties is evident. It is noticeable that different methodologies cause significant changes in the initial brain maps of each individual. Applying them correctly, according to each patient's needs, can lead to results aimed at improving their life and health. But it's important to remember that neuroplasticity-based treatment is not a one-size-fits-all solution. Each patient is different, and treatment needs to be tailored to their individual needs, considering factors such as the disease stage and what they want to achieve.

5. Acknowledgement

I would like to express my sincere gratitude to Professor Dr. Mateus Grahl for his guidance and support throughout the writing process of this article. His mentorship and insights were instrumental in the development of this work. I would also like to thank Professor M.e Marcos Dums for introducing me to the UNIGOU program and supporting me throughout the entire research and course.

6. References

1. Rodrigues S das D, Ciasca SM. Aspectos da relação cérebro-cooportamento: histórico e considerações neuropsicológicas. Revista

Psicopedagogia. 2010;27(82):117–26.

2. Nahum M, Lee H, Merzenich MM. Principles of neuroplasticity-based rehabilitation. Prog Brain Res. 2013;207:141–71.

3. Oliveira RS, Bianchi LR de O, Campos CBHF, Sant'ana D de MG. Neuroplasticidade e educação: A literacia relacionada ao desenvolvimento cerebral. Arquivos do Mudi. 2019 Dec 19;23(3):172–88.

4. Reis A, Petersson KM, Faísca L. Neuroplasticidade: Os efeitos de aprendizagens específicas no cérebro humano. Em: Temas actuais em Psicologia, 11-26 (2010). 2009. p. 11–26.

5. Lima RR, Costa AMR, Souza RD de, Gomes-Leal W. Inflamação em doenças neurodegenerativas. Revista Paraense de Medicina. 2007 Jun;21(2):29–34.

6. World Health Organization. (2012). Dementia: a public health priority. World Health Organization. https://iris.who.int/handle/10665/75263

7. Oliveira EML de, Souza NA de. Esclerose Múltipla. Revista Neurociências. 1998 Sep 30;6(3):114–8.

8. Paz EG da, Mendes D de J da S, Brito SN, Barbosa WO. Doenças neurodegenerativas em adultos e idosos: um estudo epidemiológico descritivo. Revista Neurociências. 2021 Sep 18;29:1–11.

9. Amato A, Ragonese P, Ingoglia S, Schiera G, Schirò G, Di Liegro CM, et al. Lactate Threshold Training Program on Patients with Multiple Sclerosis: A Multidisciplinary Approach. Nutrients. 2021 Nov 27;13(12):4284.

10. Feys P, Moumdjian L, Van Halewyck F, Wens I, Eijnde BO, Van Wijmeersch B, et al. Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis. Mult Scler. 2019 Jan;25(1):92–103.

11. Castelli L, Giovannini S, Iacovelli C, Fusco A, Pastorino R, Marafon DP, et al. Training-dependent plasticity and far transfer effect enhanced by Bobath rehabilitation in Multiple Sclerosis. Mult Scler Relat Disord. 2022 Dec;68:104241.

12. Rocca MA, Meani A, Fumagalli S, Pagani E, Gatti R, Martinelli-Boneschi F, et al. Functional and structural plasticity following action observation training in multiple sclerosis. Mult Scler. 2019 Oct;25(11):1472–87.

13. Boffa G, Tacchino A, Sbragia E, Schiavi S, Droby A, Piaggio N, et al. Preserved brain functional plasticity after upper limb task-oriented rehabilitation in progressive multiple sclerosis. Eur J Neurol. 2020 Jan;27(1):77–84.

14. Gatti R, Tettamanti A, Lambiase S, Rossi P, Comola M. Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial. Physiotherapy Res Intl. 2015 Jun;20(2):100–7.

15. Tavazzi E, Bergsland N, Cattaneo D, Gervasoni E, Laganà MM, Dipasquale O, et al. Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. J Neurol. 2018 Jun;265(6):1393–401.

16. Devasahayam AJ, Chaves AR, Lasisi WO, Curtis ME, Wadden KP, Kelly LP, et al. Vigorous cool room treadmill training to improve walking ability in people with multiple sclerosis who use ambulatory assistive devices: a feasibility study. BMC Neurology. 2020 Jan 22;20(1):33.

17. Concurrent multi-session anodal trans-cranial direct current stimulation enhances pelvic floor muscle training effectiveness for female patients with multiple sclerosis suffering from urinary incontinence and pelvic floor dysfunction: a randomized clinical trial study | SpringerLink [Internet]. [cited 2023 Sep 18]. Available from: https://link.springer.com/article/10.1007/s00192-022-05429-6

18. Fling BW, Martini DN, Zeeboer E, Hildebrand A, Cameron M. Neuroplasticity of the sensorimotor neural network associated with walking aid training in people with multiple sclerosis. Mult Scler Relat Disord. 2019 Jun;31:1–4.

19. Aguirre N, Cruz-Gómez ÁJ, Esbrí SF, Miró-Padilla A, Bueichekú E, Broseta-Torres R, et al. Enhanced frontoparietal connectivity in multiple sclerosis patients and healthy controls in response to an intensive computerized training focused on working memory. Mult Scler Relat Disord. 2021 Jul;52:102976.

20. De Giglio L, Upadhyay N, De Luca F, Prosperini L, Tona F, Petsas N, et al. Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis. Journal of the Neurological Sciences. 2016 Nov;370:211–3.

21. Cerasa A, Gioia MC, Valentino P, Nisticò R, Chiriaco C, Pirritano D, et al. Computer-assisted cognitive rehabilitation of attention deficits for multiple sclerosis: a randomized trial with fMRI correlates. Neurorehabil Neural Repair. 2013 May;27(4):284–95.

22. Cuypers K, Leenus DJF, van den Berg FE, Levin O,

Thijs H, Swinnen SP, et al. Long-term TENS treatment decreases cortical motor representation in multiple sclerosis. Neuroscience. 2013 Oct 10;250:1–7.

23. Cuypers K, Leenus DJF, Van Wijmeersch B, Thijs H, Levin O, Swinnen SP, et al. Anodal tDCS increases corticospinal output and projection strength in multiple sclerosis. Neurosci Lett. 2013 Oct 25;554:151–5.

24. Porcaro C, Cottone C, Cancelli A, Rossini PM, Zito G, Tecchio F. Cortical neurodynamics changes mediate the efficacy of a personalized neuromodulation against multiple sclerosis fatigue. Sci Rep. 2019 Dec 3;9(1):18213.

25. Meesen RLJ, Thijs H, Leenus DJF, Cuypers K. A single session of 1 mA anodal tDCS-supported motor training does not improve motor performance in patients with multiple sclerosis. Restor Neurol Neurosci. 2014;32(2):293–300.

26. Patel R, Suwa Y, Kinross J, von Roon A, Woods AJ, Darzi A, et al. Neuroenhancement of surgeons during robotic suturing. Surg Endosc. 2022;36(7):4803–14.

27. Stampanoni Bassi M, Buttari F, Nicoletti CG, Mori F, Gilio L, Simonelli I, et al. Interleukin-1β Alters Hebbian Synaptic Plasticity in Multiple Sclerosis. Int J Mol Sci. 2020 Sep 23;21(19):6982.

28. Boonstra FMC, Evans A, Noffs G, Perera T, Jokubaitis V, Stankovich J, et al. OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. Mult Scler Relat Disord. 2020 May;40:101984.

29. Muotri AR. Células-tronco pluripotentes e doenças neurológicas. Estud av. 2010;24:71–9.